Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Endothelial stem cell therapy - CellProThera

Next Previous
Drug Profile

Endothelial stem cell therapy - CellProThera

Alternative Names: ProtheraCytes

Latest Information Update: 08 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CellProthera
  • Class Anti-ischaemics; Haematopoietic stem cells therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Myocardial infarction

Most Recent Events

  • 15 Mar 2024 CellProthera completes a phase II (EXCELLENT) trial in Myocardial infarction in the United Kingdom and France (Intracardiac) (NCT02669810)
  • 01 Feb 2023 CellProthera and BioCardia enhance the agreement to complete the ongoing phase I/IIb EXCELLENT trial for the treatment of Acute myocardial infarction in Europe and potential early access for patients
  • 05 Mar 2021 Endothelial stem cell therapy is still in phase I/II trials for Myocardial infarction in France and United Kingdom (Intracardiac)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top